These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37322281)

  • 1. ASO Author Reflections: AJCC 8th Edition Performs Well in Predicting Outcomes Among Patients with Disseminated Appendiceal Cancer Undergoing CRS/HIPEC.
    SenthilKumar G; Cloyd JM; Mogal H
    Ann Surg Oncol; 2023 Sep; 30(9):5754-5755. PubMed ID: 37322281
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC.
    Morgan RB; Yan A; Dhiman A; Shergill A; Polite B; Turaga KK; Eng OS
    J Gastrointest Surg; 2022 Dec; 26(12):2591-2594. PubMed ID: 35879590
    [No Abstract]   [Full Text] [Related]  

  • 3. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASO Author Reflections: Evaluating Conversion of Low-Grade to High-Grade Appendiceal Neoplasms for Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Mangieri CW; Levine EA
    Ann Surg Oncol; 2022 Jan; 29(1):212-213. PubMed ID: 34467501
    [No Abstract]   [Full Text] [Related]  

  • 6. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
    Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASO Author Reflections: If at First You Don't Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer.
    Lopez-Ramirez F; King MC; Gushchin V; Sardi A
    Ann Surg Oncol; 2022 Jun; 29(6):3402-3403. PubMed ID: 35015184
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparing Survival Outcomes and Impact of EPIC in Patients Undergoing CRS/HIPEC for Mucinous Appendiceal Neoplasm.
    Mercado M; Shamavonian R; Cheng E; Ahmadi N; Morris DL
    Anticancer Res; 2023 Feb; 43(2):817-822. PubMed ID: 36697077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
    Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASO Author Reflections: CRS/HIPEC Cannot be Done-Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer.
    Baron E; King MC; Gushchin V; Sardi A; Ledakis P
    Ann Surg Oncol; 2022 Oct; 29(11):6590-6591. PubMed ID: 35644859
    [No Abstract]   [Full Text] [Related]  

  • 12. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
    Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
    Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASO Author Reflections: When is the Best Time to Perform Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Recurrent Low-Grade Appendiceal Mucinous Neoplasm?
    Valenzuela CD; Votanopoulos KI; Levine EA; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3432-3433. PubMed ID: 35257253
    [No Abstract]   [Full Text] [Related]  

  • 16. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Misdiagnosis of appendiceal neoplasms as ovarian tumors: Impact of prior gynecologic surgery on definitive cytoreduction and HIPEC.
    Garland-Kledzik M; Maithel S; Jafari MD; Dehkordi-Vakil F; Chaudhry H; Dinicu A; Chang I; Krasnoff C; Gambhir S; Sheehan B; Pigazzi A
    Eur J Surg Oncol; 2022 Feb; 48(2):449-454. PubMed ID: 34454813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASO Author Reflections: Neoadjuvant Chemotherapy for High-Grade Appendiceal Neoplasms Before Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy, Closer to Evidence-Based Practice?
    Mangieri CW; Levine EA
    Ann Surg Oncol; 2022 Apr; 29(4):2649-2650. PubMed ID: 35001235
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: The Potential of ERAS in Standardizing Care for Patients Undergoing CRS-HIPEC.
    Sun BJ; Lee B
    Ann Surg Oncol; 2023 Dec; 30(13):8170-8171. PubMed ID: 37707666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.